Genetics and Breast Cancer in Younger Women
Even though many of the younger patients have a family history of breast cancer, they often do not test positive on genetic testing, which suggests that their disease is associated with a genetic mutation that hasn’t been identified yet and is not covered by the current screenings, Dr. Levenbach said.
However, the upcoming five to 10 years will likely see significant advancements in clinicians’ ability to identify various genes associated with increased risk, and the development of more therapies that target specific gene mutations driving breast cancer, Dr. Levenbach said.
Additionally, current screening panels look for far more genetic mutations than panels that were used several years ago, which means women who underwent breast cancer screening many years ago may want to talk with their physician about whether additional screening is warranted.
A Steadily Improving Outlook for Patients of All Ages
Fortunately, progress has been made when it comes to identifying the genetic basis of breast cancer, and those improvements have been matched by strides in treating the disease. Dr. Levenbach said that there are very good therapies available, and even more in the late stages of clinical development. Since it offers a full array of treatments, RCCA can individualize each patient’s care to optimal effect.
“While each woman’s situation is unique, younger patients tend to have more aggressive breast cancer,” Levenbach said. “Compared to older women, breast cancers in younger patients are more likely to test positive for a protein called human epidermal growth factor receptor 2 (HER-2), which promotes cancer cell growth. When a cancer is more aggressive, we formulate our treatment strategy accordingly, so younger patients often will have multimodal therapy, including surgery, chemotherapy and radiation. We also use hormonal therapies, as appropriate, after carefully considering and discussing with the patient the associated impact on cardiovascular and bone health, and reproductive status. Throughout treatment and afterwards, we coordinate closely with the woman’s other physicians — such as Ob/Gyns, reproductive endocrinologists and cardiologists — to ensure attention to her comprehensive well-being.”
Survival rates and quality of life have steadily improved across different age groups, breast cancer types and breast cancer stages, she said.
“While you never want to see the area where you live have an increased rate of any type of cancer, women in Burlington County — along with their counterparts across New Jersey and the country — can do a great deal to reduce their risk of breast cancer and to ensure early detection of the disease,” Dr. Levenbach said. “Patients are experiencing greatly improved outcomes, and the earlier we find and treat breast cancer, the better the outcomes tend to be. If I could leave women with one last thought on this subject, it is that breast cancer screening is safe and is potentially lifesaving.”
*******
Born and raised in New Jersey, Dr. Levenbach received her medical degree from Temple University Medical School. She completed her internal medicine residency at Temple University Hospital and conducted her fellowship training in medical oncology and hematology at Fox Chase Cancer Center/Temple University Hospital. During her residency and fellowship, she was involved in clinical research in breast cancer and gynecological malignancies. She is a member of the American Society of Clinical Oncology and American Society of Hematology, and is board-certified in internal medicine, medical oncology and hematology.
Dr. Levenbach is one of the more than 80 cancer specialists who treat patients at 20-plus RCCA care centers in New Jersey, Connecticut, Massachusetts and the Washington, D.C., area. Those oncology specialists see more than 22,000 new patients each year and provide care to more than 225,000 established patients, collaborating closely with their patients’ other physicians. They offer patients the latest in cutting-edge treatments, including immunotherapies and targeted therapy, as well as access to a wide range of clinical trials. In addition to serving patients who have solid tumors, blood-based cancers and benign blood disorders such as anemia, RCCA care centers also provide infusion services to people with a number of non-oncologic conditions — including multiple sclerosis, Crohn’s disease, asthma and rheumatoid arthritis — who take intravenously-administered medications.
To learn more about RCCA, call 609-807-2693 or visit Moorestown.